Innovation

A new test that ARUP offers for preeclampsia risk measures the ratio between two angiogenic factors (sFlt-1 and PlGF) that are produced by the placenta and are involved in the pathophysiology of preeclampsia.

The Tasso+ self-collection device can be shipped directly to patients, facilitating remote collection of whole blood samples and eliminating the need for lab visits.

Presenters include Kimberly Hanson, MD, MHS; David Ng, MD; Patricia Slev, PhD, D(ABCC); Tammy Smith, MD, PhD; and Nicholas Spies, MD.

The research grant is named in honor of retired ARUP CEO Sherrie Perkins, MD, PhD, whose leadership laid the groundwork for ARUP’s increased focus on innovation.

Representative Blake Moore (R-Utah, District 1) speaks during a House Committee on Ways and Means hearing held at ARUP Laboratories. Pictured from left to right are Celeste Maloy (R-Utah, District 2), Burgess Owens (R-Utah, District 4), Moore, Jason Smith (R-Missouri, District 8), and Brad Wenstrup, MD (R-Ohio, District 2).

Rep. Blake Moore (R-UT) and other members of the Ways and Means Committee’s Health Subcommittee will participate in a field hearing on July 12 at ARUP Laboratories.

Andy Theurer, ARUP CEO, speaks to a crowd gathered to celebrate ARUP’s 40th anniversary. Others on stage include, from left to right, Tracy I. George, MD, ARUP chief scientific officer and president of the Innovation Business Unit, Julio C. Delgado, MD, MS, ARUP executive vice president and vice chair and chief of Clinical Pathology at the University of Utah, and Carl R. Kjeldsberg, MD, an ARUP founder and former CEO.

Presentations and posters will cover topics such as mycobacterial infections, increasing rates of macrolide drug resistance, the state of parasitology following the COVID-19 pandemic, and more.

Erica Clyde speaks with attendees at BioHive Live.

An expert in TAR DNA-binding protein of 43 kDa (TDP-43), neuropathologist Qinwen Mao, MD, PhD, subspecialty director of Neuropathology at ARUP, is working to identify biomarkers that predict the presence of TDP-43 pathology to contribute to the diagnosis of frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease.

ARUP survey shows “profound” concern within the lab community about the FDA’s proposed rule.